City Therapeutics, a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, has announced the completion of a $99.5 million Series B financing. City Therapeutics is one of AN Venture Partners' portfolio companies.

Viking Global Investors and Sofinnova Investments participated in the financing as new investors, along with Casdin Capital and NYBC Ventures, joined by existing investors including ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, and AN Venture Partners.

Proceeds will be used to advance City Therapeutics' RNAi pipeline and next-generation engineering platform, including an ongoing Phase 1 clinical trial of CITY-FXI for thromboembolic diseases and two additional programs that are expected to enter the clinical stage by year-end 2026.

For the full announcement, please see City Therapeutics' press release here




About AN Venture Partners
ANV is a Tokyo and San Francisco-based multi-stage, global biotech venture capital firm specializing in bridging innovative science from Japan with the US start-up ecosystem. ANV Fund I is a USD200 million fund that closed in June 2025. The firm was established in 2022 by a group of experienced venture capitalists from Japan and the United States, who have a wealth of experience building start-ups. ANV is committed to strengthening Japan’s biotech ecosystem and founded initiatives such as Science2Startup Japan to accelerate ecosystem growth. For more information, please visit www.an.vc  


Media Contacts
Email: info@an.vc